All change at the top, as BMAC debutant Abcam takes the sector prize. A great result for the Cambridge-based supplier of monoclonal antibodies - among other things - to genetic researchers across the globe. GlaxoSmithKline has slipped, but only by one place, to second. Bribery accusations by the Chinese government appear to have done little reputational damage so far. Generic drugs maker Shire is up two places, while Cilit Bang-to-Durex giant Reckitt Benckiser is rumoured to be considering selling off its pharma arm entirely. Sales of its big heroin addiction drug, Suboxone, have been hit by cheaper rivals. Fifth-placed Smith & Nephew has a new chairman in industry veteran Roberto Quarta, and posted Q3 sales up 5% to $1.03bn.